Big pharma, Partnering, Pharma

Novartis and BioLineRx in drug discovery pact

Posted on 17 December 2014

Tags: , ,

BioLineRx has entered into a multi-year strategic collaboration agreement with Novartis Pharma designed to facilitate development and commercialization of Israeli-sourced drug candidates.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities


Leveraging BioLineRx’s close and long-lasting ties with academic institutions, hospitals and biomedical companies in Israel, as well as its proven project screening process and development expertise, Novartis will evaluate projects identified and presented by BioLineRx for co-development and potential future licensing under the collaboration.

The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept.

As part of the agreement, Novartis has made an initial equity investment in BioLineRx of $10 million for 12.8% of BioLineRx’s current shares outstanding.

Novartis acquired an initial 5,000,000 American Depositary Shares of BioLineRx in a private transaction at a price of $2.00 per share for a total equity investment of $10 million.

Novartis will not have any governance rights and has agreed to certain standstill provisions.

Novartis and BioLineRx will jointly evaluate both clinical and pre-clinical stage projects presented by BioLineRx via a Joint Steering Committee, which will determine which projects to advance further in development and on what terms.

Projects at or reaching the clinical stage will be eligible for selection by Novartis.

Upon selection of a project, Novartis will pay BioLineRx an option fee of $5 million, as well as fund 50% of the anticipated remaining development costs associated with establishing clinical proof-of-concept, in the form of an additional equity investment in BioLineRx.

Novartis will have an exclusive right of first negotiation to license from BioLineRx each selected project upon establishment of clinical proof-of-concept.

The companies intend to develop up to three programs pursuant to this collaboration.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2014

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

Print Friendly, PDF & Email

Leave a Reply